Insider Transactions in Q4 2020 at Alexion Pharmaceuticals, Inc. (ALXN)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 17
2020
|
Daniel Bazarko SVP, Controller, CAO |
SELL
Open market or private sale
|
Direct |
24,066
-16.82%
|
$3,778,362
$157.78 P/Share
|
|
Dec 17
2020
|
Daniel Bazarko SVP, Controller, CAO |
BUY
Exercise of conversion of derivative security
|
Direct |
24,066
+19.8%
|
$2,839,788
$118.87 P/Share
|
|
Dec 16
2020
|
Ellen Chiniara EVP & Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
19,913
-16.7%
|
$3,126,341
$157.96 P/Share
|
|
Dec 16
2020
|
Ellen Chiniara EVP & Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,965
+37.63%
|
-
|
|
Dec 16
2020
|
Aradhana Sarin EVP, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,363
-10.01%
|
$1,469,991
$157.96 P/Share
|
|
Dec 16
2020
|
Aradhana Sarin EVP, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
15,371
+23.94%
|
-
|
|
Dec 16
2020
|
John J Orloff EVP, Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
21,395
-13.07%
|
$3,359,015
$157.96 P/Share
|
|
Dec 16
2020
|
John J Orloff EVP, Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
40,677
+32.31%
|
-
|
|
Dec 16
2020
|
Indrani Lall Franchini EVP, Chief Compliance Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
19,838
-15.74%
|
$3,114,566
$157.96 P/Share
|
|
Dec 16
2020
|
Indrani Lall Franchini EVP, Chief Compliance Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,965
+36.45%
|
-
|
|
Dec 16
2020
|
Brian Goff EVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
21,395
-12.53%
|
$3,359,015
$157.96 P/Share
|
|
Dec 16
2020
|
Brian Goff EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,677
+31.44%
|
-
|
|
Dec 16
2020
|
Daniel Bazarko SVP, Controller, CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,812
-11.57%
|
$1,383,484
$157.96 P/Share
|
|
Dec 16
2020
|
Daniel Bazarko SVP, Controller, CAO |
BUY
Grant, award, or other acquisition
|
Direct |
15,371
+27.91%
|
-
|
|
Dec 16
2020
|
Ludwig Hantson CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
85,592
-12.59%
|
$13,437,944
$157.96 P/Share
|
|
Dec 16
2020
|
Ludwig Hantson CEO |
BUY
Grant, award, or other acquisition
|
Direct |
162,707
+31.53%
|
-
|
|
Dec 15
2020
|
Ellen Chiniara EVP & Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
56
+0.13%
|
$5,320
$95.53 P/Share
|
|
Dec 15
2020
|
John J Orloff EVP, Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
40
+0.06%
|
$3,720
$93.53 P/Share
|
|
Dec 03
2020
|
Tanisha Carino EVP & CCAO |
SELL
Open market or private sale
|
Direct |
1,530
-8.68%
|
$186,660
$122.26 P/Share
|
|
Dec 02
2020
|
Tanisha Carino EVP & CCAO |
SELL
Payment of exercise price or tax liability
|
Direct |
665
-3.63%
|
$80,465
$121.76 P/Share
|
|
Nov 30
2020
|
Aradhana Sarin EVP, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,298
-3.73%
|
$160,952
$124.0 P/Share
|